S

Swedencare AB (publ)
STO:SECARE

Watchlist Manager
Swedencare AB (publ)
STO:SECARE
Watchlist
Price: 48.96 SEK 1.53% Market Closed
Market Cap: 7.8B SEK
Have any thoughts about
Swedencare AB (publ)?
Write Note
Section:
 

Relative Value

The Relative Value of one SECARE stock under the Base Case scenario is 99.71 SEK. Compared to the current market price of 48.96 SEK, Swedencare AB (publ) is Undervalued by 51%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

SECARE Relative Value
Base Case
99.71 SEK
Undervaluation 51%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

3.1
P/S
P/S
Price to Sales
3.1
vs History
73
vs Industry
35
Median 3Y
3.7
Median 5Y
4.2
Industry
2.5
Forward
3
More Details
102
P/E
P/E
Price to Earnings
102
vs History
58
vs Industry
3
Median 3Y
141.4
Median 5Y
131.4
Industry
21.8
Forward
55.2
More Details
18.8
P/OCF
P/OCF
Price to OCF
18.8
vs History
73
vs Industry
22
Median 3Y
21.9
Median 5Y
37.1
Industry
16.1
More Details
29
P/FCFE
P/FCFE
Price to FCFE
29
vs History
39
vs Industry
17
Median 3Y
15.3
Median 5Y
24.8
Industry
23.8
More Details
1
P/B
P/B
Price to Book Value
1
vs History
69
vs Industry
59
Median 3Y
1
Median 5Y
1.9
Industry
2.1
More Details
3.7
EV/S
EV/S
Enterprise Value to Sales
3.7
vs History
76
vs Industry
29
Median 3Y
4.4
Median 5Y
5
Industry
2.7
Forward
3.5
More Details
6.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.6
vs History
77
vs Industry
29
Median 3Y
7.9
Median 5Y
9.6
Industry
5.2
More Details
17.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
17.1
vs History
77
vs Industry
19
Median 3Y
21.5
Median 5Y
28.2
Industry
13.5
Forward
15.9
More Details
41
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
41
vs History
77
vs Industry
8
Median 3Y
64.5
Median 5Y
68.9
Industry
16.8
Forward
28.8
More Details
22.2
EV/OCF
EV/OCF
Enterprise Value to OCF
22.2
vs History
76
vs Industry
20
Median 3Y
25.3
Median 5Y
46.5
Industry
15.2
More Details
26.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
26.2
vs History
74
vs Industry
18
Median 3Y
30.1
Median 5Y
61.8
Industry
19.3
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
73
vs Industry
57
Median 3Y
1
Median 5Y
1.7
Industry
1.9
More Details

Multiples Across Competitors

SECARE Competitors Multiples
Swedencare AB (publ) Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Swedencare AB (publ)
STO:SECARE
7.8B SEK 3.1 102 17.1 41
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
743.6B USD 18.2 88.8 47.8 53.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
346B USD 3.9 23.6 11.4 14.8
US
Merck & Co Inc
NYSE:MRK
248.8B USD 3.9 20.5 10.4 12.4
CH
Roche Holding AG
SIX:ROG
199.5B CHF 3.4 17.3 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.6B GBP 4.1 31.5 169.4 253.9
CH
Novartis AG
SIX:NOVN
171.3B CHF 3.8 10.9 9.4 13.2
US
Pfizer Inc
NYSE:PFE
149.2B USD 2.5 35.1 10.5 15.8
P/S Multiple
Revenue Growth P/S to Growth
SE
S
Swedencare AB (publ)
STO:SECARE
Average P/S: 382 942.2
3.1
41%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.2
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
3.9
13%
0.3
US
Merck & Co Inc
NYSE:MRK
3.9
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
SE
S
Swedencare AB (publ)
STO:SECARE
Average P/E: 39.9
102
512%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
88.8
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.6
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.5
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.3
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.9
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.1
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
SE
S
Swedencare AB (publ)
STO:SECARE
Average EV/EBITDA: 415.2
17.1
78%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.8
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.4
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.4
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
SE
S
Swedencare AB (publ)
STO:SECARE
Average EV/EBIT: 1 814.1
41
226%
0.2
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.3
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.8
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.9
131%
1.9
CH
Novartis AG
SIX:NOVN
13.2
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2

See Also

Summary
SECARE intrinsic value, competitors valuation, and company profile.
DCF Valuation
SECARE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SECARE stock valuation using valuation multiples.
Wall Street Estimates
SECARE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SECARE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.